In addition, the proportion of CD4+CCR7+CD62L+GL7+ T cells (Figures 3(a)–3(c), and 3(f)) in colitis mice after SSP and 5-ASA treatment was significantly higher than that in those colitis mice before treatment (P < 0.01 or P < 0.05). The gene discussed is SELL; the disease is colitis.